Clinically proven to treat Generalized Anxiety Disorder (GAD), Bucapsol™ (buspirone HCl) delivers effective, sustained symptom relief without sedation, cognitive dulling, or risk of dependency—empowering patients to stay functional, focused, and in control.

• Bucapsol™ (buspirone HCl) is a non-sedating, non-habit-forming anxiolytic developed for first-line GAD treatment and long-term use.
• Innovative capsule formulation offers key clinical advantages over traditional tablets: faster disintegration, smoother swallowing, and enhanced pharmacokinetics.
• $0 Co-Pay Assistance Program for eligible patients* underscores Pangea’s commitment to access, adherence, and affordability.

FORT LAUDERDALE, FL — July 17, 2025 — Pangea Pharmaceuticals is pleased to announce the nationwide launch of Bucapsol™ (buspirone HCl) Oral Capsules, a new oral formulation of buspirone designed to modernize the treatment experience for adults living with Generalized Anxiety Disorder (GAD).

Formulated to overcome the limitations of traditional anxiolytics, Bucapsol™ supports clarity without compromise—relieving anxiety without the sedation, memory disruption, or dependence often associated with benzodiazepines.

Why Bucapsol™ Stands Out
Unlike conventional tablets, Bucapsol™ capsules feature:

• Rapid disintegration and optimized absorption kinetics
• A gelatin-based shell that eases swallowing and minimizes GI upset
• Improved tolerability and reduced pill fatigue in long-term therapy
• Flexible dosing: Now available in 15 mg strength, with 7.5 mg and 10 mg options launching soon to support personalized titration

In clinical use, Bucapsol™ has demonstrated consistent symptom control, long-term tolerability, and favorable patient-reported outcomes, making it a compelling option for both new initiations and therapeutic transitions.

For full prescribing information, access tools, and clinical FAQs, visit www.bucapsol.com.